Testing a new antibody for colorectal cancer
Part of Cancer, Digestive system, Kidney & urinary, Skin clinical trials.
This trial tests a new drug called CC-3, which is a type of antibody designed to help your immune system attack colorectal cancer cells. It is for people whose cancer has spread and who have already tried several standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body (metastatic).
- You have already tried at least two types of standard treatments (chemotherapy and/or targeted therapy).
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are generally able to take care of yourself (ECOG performance status 0, 1, or 2).
- Your blood tests show your bone marrow, kidneys, and liver are working well enough.
- You are willing to use effective birth control during and for 2 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests whether a combination of three drugs (cetuximabβ, envolimab, and mFOLFOX6) can help people with advanced colorectal cancer that has not been treated before. It is for people whose tumors have certain gene markers (RAS/BRAF wild-type and MSS).
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial is testing a new combination of drugs (envafolimab, cetuxima-β, and chemotherapy) for people with a specific type of advanced colorectal cancer that has not been treated yet. The goal is to see if it is safe and works well.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.